BridgeMD
Binimetinib, Encorafenib and Pembrolizumab COmbination in MElanoma - Metastatic to the Brain
EU CTIS ID: 2023-505302-42-00
What this study is testing
The primary objective of the trial is to demonstrate improved intracranial (IC) progression-free survival (PFS) in BRAFV600 mutation-positive melanoma patients with brain metastasis when upfront SRS is added to binimetinib-encorafenib plus pembrolizumab combination therapy.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Provided written informed consent prior to any trial specific procedures.
- At least one measurable intracranial lesion
- All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be resolved or Grade 1 according to National Cancer Institute – Common terminology criteria for adverse events, version 5.0 (NCI-CTCAE v5.0).
- Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption (malabsorption syndrome, major resection of the stomach or bowels).
- Adequate bone marrow, organ function, and laboratory parameters.
- Adequate cardiac function
You likely can't join if
- More than 10 intracranial metastases.
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (patients with laboratory evidence of cured HBV and/or HCV will be permitted).
- A history or evidence of cardiovascular risk
- A history or current evidence of retinal vein occlusion.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, and their excipients.
- Hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
See the full eligibility criteria
Who can join
- Provided written informed consent prior to any trial specific procedures.
- At least one measurable intracranial lesion
- All prior anti-cancer treatment-related toxicities (except alopecia and laboratory values) must be resolved or Grade 1 according to National Cancer Institute – Common terminology criteria for adverse events, version 5.0 (NCI-CTCAE v5.0).
- Able to swallow and retain oral medication and must not have any clinically significant gastrointestinal abnormalities that may alter absorption (malabsorption syndrome, major resection of the stomach or bowels).
- Adequate bone marrow, organ function, and laboratory parameters.
- Adequate cardiac function
- Women of childbearing potential (WOCBP) or men must agree to refrain from sexual activity or use adequate contraception for the duration of study treatment and for 120 days after completing treatment. Male participants must agree to refrain from donating sperm during this period.
- Affiliated to or a beneficiary of the local social security system or equivalent.
- Patient is willing and able to comply with the protocol for the duration of the trial including undergoing treatment and scheduled visits, and examinations including follow-up.
- Aged ≥18 years old.
- An Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Histologically confirmed Stage IV M1d cutaneous melanoma or unknown primary melanoma that is metastatic to the brain. Patients with mucosal melanomas are not considered eligible for this study.
- Presence of BRAFV600E/K/D/R mutation according to a locally validated BRAF Assay.
- Candidacy for SRS therapy validated by the radiation oncologist and neurosurgeon at the investigative centre. This should be documented in the patient file.
- Absence of previous combined systemic treatment for distant metastatic melanoma.
- No more than one previous local intracranial therapy for one lesion (e.g. craniotomy, SRS).
- Able to undergo gadolinium-enhanced magnetic resonance imaging (MRI).
What rules you out
- More than 10 intracranial metastases.
- Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (patients with laboratory evidence of cured HBV and/or HCV will be permitted).
- A history or evidence of cardiovascular risk
- A history or current evidence of retinal vein occlusion.
- Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatments, and their excipients.
- Hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption
- Participation in another therapeutic trial within the 30 days prior to randomization
- Pregnant or breastfeeeding female.
- History of, or active interstitial lung disease or (non-infectious) pneumonitis.
- Active, known or suspected autoimmune disease or a documented history of autoimmune disease, including ulcerative colitis and Crohn’s disease (Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll).
- Diagnosis of immunodeficiency or systemic chronic steroid therapy (≥10mg/day prednisone or equivalent) or any immunosuppressive therapy 7 days prior to planned date for first dose of study treatment. Topical, inhaled, nasal and ophthalmic steroids are allowed.
- Presence of neurological symptoms related to intracranial metastases which induce alteration of the ECOG performance status to 2 or more or require immediate radiation treatment.
- Has received a live vaccine within 30 days prior to the first dose of study drug.
- Active infection requiring systemic therapy.
- Known history of active TB (Bacillus Tuberculosis).
- Allogenic tissue/solid organ transplant.
- Person deprived of their liberty or under protective custody or guardianship.
- Patient unwilling or unable to comply with the medical follow-up required by the trial because of geographic, social or psychological reasons.
- Ocular melanoma.
- Brain metastases that necessitate immediate neurosurgery.
- Any previous treatment with whole-brain radiation.
- Presence of leptomeningeal disease or any parenchymal brain metastasis >30 mm in longest diameter.
- Current or expected use of a strong inhibitor of CYP3A4.
- History of malignancy other than disease under study occurring within 3 years of study enrolment with the exception of completely resected non-melanoma skin cancer or indolent second malignancies.
- Any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that, in the opinion of the investigator, could interfere with the patient’s safety, obtaining informed consent, or compliance with study procedures.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.